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Abstract
Background: Liver-type fatty acid-binding protein (L-FABP) and neutrophil
gelatinase-associated lipocalin (NGAL) are candidate biomarkers for the detection of
early chronic kidney disease (CKD) in cats.
Objective: To evaluate urinary and serum L-FABP and NGAL concentrations in CKD
cats and in hyperthyroid cats before and after radioiodine (131I) treatment.
Animals: Nine CKD cats, 45 healthy cats and hyperthyroid cats at 3 time points
including before (T0, n = 49), 1 month (T1, n = 49), and 11 to 29 months after (T2,
n = 26) 131I treatment.
Methods: Cross-sectional and longitudinal study. Serum L-FABP (sL-FABP), serum
NGAL (sNGAL), urinary L-FABP (uL-FABP), and urinary NGAL (uNGAL) were com-
pared between the 3 groups and between hyperthyroid cats before and after treat-
ment. Data are reported as median (min-max).
Results: CKD cats had significantly higher sL-FABP (13.50 [3.40-75.60] ng/ml) and
uL-FABP/Cr (4.90 [0.97-2139.44] μg/g) than healthy cats (4.25 [1.34-23.25] ng/ml;
P = .01 and 0.46 [0.18-9.13] μg/g; P < .001, respectively). Hyperthyroid cats at T0
Abbreviations: 131I, radioactive iodine; CKD, chronic kidney disease; GFR, glomerular filtration rate; IRIS, international Renal Interest Society; L-FABP, liver-type fatty acid-binding protein; LOD,
lower limit of detection; NGAL, neutrophil gelatinase-associated lipocalin; pNGAL, plasma NGAL; RI, reference interval; ROC, receiver operator characteristic; SBP, systolic blood pressure; sCr,
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had significantly higher uL-FABP/Cr (0.94 [0.15-896.00] μg/g) than healthy cats
(P < .001), thereafter uL-FABP/Cr significantly decreased at T2 (0.54 [0.10-76.41] μg/g,
P = .002). For the detection of CKD, uL-FABP/Cr had 100% (95% confidence interval
[CI], 66.4-100.0) sensitivity and 93.2% (95% CI, 81.3-98.6) specificity. There were no
significant differences in sNGAL and uNGAL/Cr between the 3 groups.
Conclusions and Clinical Importance: L-FABP, but not NGAL, is a potential biomarker
for the detection of early CKD in cats. Utility of uL-FABP to predict azotemia after
treatment in hyperthyroid cats remains unknown.
K E YWORD S
biomarkers, cats, CKD, hyperthyroid, L-FABP, NGAL
1 | INTRODUCTION
Chronic kidney disease (CKD) in cats is routinely diagnosed by com-
bined presence of azotemia and inappropriate urine specific gravity
(USG).1,2 Glomerular filtration rate (GFR) testing is the gold standard
for CKD diagnosis, but it is impractical in routine clinical practice.3
Traditional renal biomarkers such as serum creatinine (sCr) only detect
renal dysfunction at a late stage of disease progression.4 Early detec-
tion of CKD might enable early therapeutic intervention to delay CKD
progression in cats. Hence, the limitations of these biomarkers have
driven the search for other biomarkers that are potential for early
detection of CKD.5
Hyperthyroidism affects 4% to 11% of elderly cats,6 30% to 50%
of which develop CKD.7,8 Concurrent CKD can be masked by hyper-
thyroidism, and post-treatment azotemia develops in 15% to 40% of
hyperthyroid cats.9-11 The evaluation of CKD in hyperthyroidism is
particularly challenging, because thyrotoxicosis increases the GFR and
induces loss of muscle mass,12-14 consequently lowering sCr concen-
trations.14 Specifically in hyperthyroid cats, serum symmetric
dimethylarginine has only low sensitivity for the detection of post-
treatment azotemia and did not accurately reflect GFR.15,16 This is an
additional reason to search for alternative early renal biomarkers that
are also useful in hyperthyroid.
Liver-type fatty acid-binding protein (L-FABP) is expressed in the
liver and renal proximal tubular cells. Freely filtered L-FABP from circula-
tion is normally reabsorbed in the proximal tubules.17,18 Stress on the
renal tubules increases uL-FABP levels.19 Urinary L-FABP appears to be
useful for detecting early-stage renal disease and has prognostic value
and utility in monitoring CKD progression in humans.20-24 Katayama
et al suggest that urinary L-FABP-to-creatinine ratio (uL-FABP/Cr) may
be a potential biomarker to predict early renal injury.25,26 To corroborate
these findings and to evaluate whether L-FABP has potential as an early
CKD biomarker in hyperthyroid cats, longitudinal study of L-FABP in
hyperthyroid cats along with comparison between hyperthyroid cats,
healthy cats, and CKD cats are warranted.
Neutrophil gelatinase-associated lipocalin (NGAL) is expressed by
neutrophils and renal tubular cells during injury and inflammation.27,28
Freely pass through the glomerulus, NGAL is well reabsorbed in the
proximal tubules.29 NGAL is upregulated because of increased renal
tubular secretion and decreased reabsorption by injured proximal
tubules.30,31 Both serum and urinary NGAL (sNGAL and uNGAL) are
used to detect acute kidney injury and CKD in humans and dogs.32-42
CKD cats have a higher uNGAL/Cr than do healthy cats.43 Currently,
studies of uNGAL as a renal biomarker in CKD cats and in hyperthy-
roid cats are lacking.
After validation of 2 commercial assays for feline L-FABP and
NGAL, the first objective of this study was to evaluate both serum and
urine L-FABP and NGAL concentrations in CKD cats and in hyperthy-
roidism. Second, this study aimed to evaluate both renal biomarkers in
hyperthyroid cats before and after radioactive iodine (131I) treatment.
2 | MATERIALS AND METHODS
2.1 | Study population
For this cross-sectional study, frozen (−80C) serum and urine sam-
ples obtained during previous studies between October 2015 and
November 2017 from healthy control cats, CKD cats, and hyperthy-
roid cats were analyzed.16,44,45 Additionally, frozen serum and urine
samples from 2 hyperthyroid cats were included.
For the longitudinal study, serum and urine samples from the
same population of hyperthyroid cats were evaluated at 3 time points;
before 131I treatment (T0); 1 month (T1); and 11 to 29 months after
131I treatment (T2). These samples were collected between 2015 and
2019 and frozen at −80C until batch analysis in 2019.16,45
Adult cats were considered healthy based on absence of clinically
relevant abnormalities in the history, physical examination, CBC,
serum biochemistry, urinalysis, thoracic radiographs, and abdominal
ultrasound examination.
Cats with CKD had clinical signs compatible with CKD, increased
sCr (>2.3 mg/dL, reference interval [RI] of IDEXX Laboratories) and
USG <1.035.46 Exclusion criteria were concurrent systemic disease,
hyperthyroidism, or prerenal and postrenal azotemia. CKD cats receiv-
ing drugs or supplements other than phosphate binders withdrew
these treatments at least 14 days before enrollment. CKD cats were
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classified into 4 stages according to the International Renal Interest
Society (IRIS) guidelines.1
Hyperthyroidism was diagnosed at T0 based on compatible
clinical signs, increased serum total thyroxine (sTT4) concentration,
or increased thyroid uptake of pertechnetate. In cats previously
treated with antithyroid drugs (methimazole), the drug was stopped
10 days before 131I treatment. Cats were treated with adapted
doses of 131I injected IV (mean dose 142.6 MBq [3.9 mCi]; range,
67.7-455.1 MBq [1.8-12.3 mCi]) after the first examination and
sample collection (T0).47 Hyperthyroid cats were excluded if they
had pre-existing azotemia (sCr >2.3 mg/dL), any evidence of con-
current systemic disease, or use of any medication except for anti-
thyroid medication within the 2 weeks before enrollment. At T1
and T2, cats' thyroid status was determined based on the combina-
tion of sTT4 (RI 0.8-4.7 μg/dL) and serum thyroid-stimulating hor-
mone (sTSH) (RI ≤0.3 ng/mL) concentrations as euthyroid (both
sTT4 and sTSH within RI), subclinically hypothyroid (sTT4 within RI
and sTSH above RI), hypothyroid (sTT4 below RI and sTSH above
RI), and hyperthyroid (sTT4 above RI and undetectable sTSH).48
Cats at T1 or T2 with sCr above >2.3 mg/dL, USG <1.035, and no
evidence of prerenal or postrenal azotemia were defined as having
post-treatment azotemia.
The Faculty of Veterinary Medicine, Ghent University, Belgium
local ethical committee (EC 2015/68 and EC 2017/72) approved the
study protocol. Participating owners provided written informed
consent.
2.2 | Procedures
All cats underwent a thorough examination including medical history,
complete physical examination, body weight measurement, body con-
dition score (9-point scale), systolic blood pressure (SBP) using Dopp-
ler ultrasound technique, and thyroid gland palpation. Standard
2-view thoracic radiographs (lateral and ventrodorsal projections) and
complete abdominal ultrasound examinations were performed to
screen for concurrent diseases in all cats at baseline. Echocardiogra-
phy was also performed in hyperthyroid cats at T0 to check for the
presence of concurrent heart disease.
A subset of hyperthyroid cats had GFR measurements performed
by exogenous plasma Cr clearance testing by a protocol previously
described by our research group at 3 time points (T0, T1, and T2).49
The GFR cut-off values were defined as normal GFR value
(≥1.9 mL/minute/kg), borderline-low value (1.4-1.8 mL/minute/kg)
and low GFR (< 1.4 mL/minute/kg) based on previous data from our
research group.50
2.3 | Blood and urine samples
Blood samples were taken by jugular venipuncture. Blood work con-
sisted of complete blood count and serum biochemistry including sCr
(IDEXX laboratories, Inc., Westbrook, Maine). Cats with CKD and
healthy control cats >6 years of age underwent sTT4 measurement.
Serums TT4 and sTSH were measured in hyperthyroid cats at all time
points (IDEXX Laboratories). Residual serum was stored at −80C for
1 to 4 years until batch analysis of sL-FABP and sNGAL.
Urine samples taken by cystocentesis were sent to IDEXX Labo-
ratories for urinalysis. Urinalysis consisted of dipstick chemistry with
IDEXX UA Strips (IDEXX Laboratories, Westbrook, Maine), sediment
analysis, urinary protein-to-creatinine ratio (UPC), and USG using
refractometry in all cats and also included bacterial culture in CKD
cats and hyperthyroid cats at T0. Residual urine was stored at −80C
for 1 to 4 years until batch analysis of uL-FABP and uNGAL.
2.4 | Analytical methods
Serum and urine creatinine concentrations were determined by an enzy-
matic colorimetric method based on Jaffe's method using picric acid as a
reagent. Urinary protein concentrations were determined by a colorimet-
ric assay, the pyrogallol red molybdate method. All values were obtained
by IDEXX Laboratories using a Beckman Coulter AU Analyzer (Beckman
Coulter, Brea, California). Serum TT4 and sTSH were measured with a
Microgenics DRI TT4 enzyme immunoassay (Microgenics Corporation,
Freemont, California)51 and with an Immulite canine TSH chemilumines-
cent enzyme immunoassay (Siemens Healthcare Diagnostics Products,
Tarrytown, New York), respectively.52,53
Concentrations of sL-FABP and uL-FABP were measured using a
commercial feline L-FABP ELISA kit (CMIC Holding, Tokyo, Japan) using
an anti-human L-FABP antibody. Concentrations of sNGAL and uNGAL
were determined using a commercial feline NGAL sandwich ELISA kit
(MyBiosource, San Diego, California) using an antihuman NGAL anti-
body. The urine samples were centrifuged at 1000 g for 20 minutes
before analysis. The in-house validation report of the assays for L-FABP
and NGAL in feline samples has been added as Data S1, Table S1, and
Figure S1. The lower limit of detection (LOD) was 2.68 ng/mL for L-
FABP assay and 3.10 ng/mL for NGAL assay in feline serum and urine
samples, respectively. Therefore, before running statistical analysis, sam-
ples with an L-FABP concentration < 2.68 ng/mL were assigned the arbi-
trary value of 1.34 ng/mL, while samples assayed with an NGAL
concentration < 3.10 ng/mL were assigned the arbitrary value
1.55 ng/mL.
2.5 | Statistical analysis
Statistical analyzes were performed using R version 3.6.3 (2020, The
R Foundation for Statistical Computing). Most variables were not nor-
mally distributed according to the Shapiro-Wilks test.
For the cross-sectional study, the overall analysis was based on
the Kruskal Wallis test and pairwise comparisons on the Wilcoxon
rank sum test by Bonferroni's method to adjust for multiple compari-
sons, that is, testing each of the 3 pairwise comparisons at a signifi-
cance level of .05/3. Spearman's correlations were assessed between
both biomarkers (L-FABP and NGAL) and 2 other renal variables (sCr
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and UPC) and between serum L-FABP (sL-FABP) or NGAL and urine
L-FABP/Cr or NGAL/Cr, respectively, in the group of CKD cats and
healthy cats. The sensitivity and specificity of L-FABP and NGAL for
the detection of azotemic CKD in CKD cats and healthy cats were
obtained by receiver operating characteristic (ROC) curve analysis.
For the longitudinal study, all variables were compared between
time points (T0, T1, and T2) by pairwise comparisons on the Wilcoxon
signed-rank test using Bonferroni's method to adjust for multiple com-
parisons, testing each of the 3 pairwise comparisons at a significance
level of .05/3. Correlations between both urinary biomarkers (uL-
FABP/Cr or uNGAL/Cr) and other thyroid and renal variables (sTT4,
sCr, GFR, and UPC) and between sL-FABP or NGAL and urine L-
FABP/Cr or NGAL/Cr, respectively, were determined in hyperthyroid
cats at different time points by Spearman's correlation.
3 | RESULTS
3.1 | Study population
One hundred and nine cats (10 CKD cats, 52 hyperthyroid cats, and
47 healthy cats) were initially enrolled in the study. Samples from
6 cats were excluded, as 1 CKD cat was also hyperthyroid, 3 hyperthy-
roid cats had concurrent systemic disease (second-degree AV block
type 2, a liver mass, and CKD), and 2 healthy cats had liver mass and
bilateral small kidneys. The CKD group consisted of 2 stage 2 cats,
6 stage 3 cats, and 1 stage 4 cat based on the IRIS staging system.
The remaining 49 hyperthyroid cats were presented at both T0 and
T1, and 26 of them were also presented at T2. The other 23 cats were
lost to follow-up at T2 because of owner non-compliance (n = 21) or
because of death before assessment at T2 (n = 2).
In the CKD group, 4 cats were domestic short-hair or long-hair cats,
2 were Ragdolls cats, 2 were Bengal cats, and 1 was a British Shorthair.
Represented breeds in the hyperthyroid group included 46 domestic
short-hair or long-hair cats and 1 British Shorthair, Chartreux, and Nor-
wegian Forest cat. The healthy group comprised 41 domestic short-hair
or long-hair cats, 2 Ragdolls, and 1 British Shorthair cat.
For the cross-sectional study, selected clinical variables and rou-
tine kidney variables of the study population are presented as descrip-
tive statistics in Table 1.
For the longitudinal study, selected variables at the 3 time points
are presented in Table 2. Forty-one cats were euthyroid, 4 cats were
subclinically hypothyroid, 1 cat was hypothyroid, 1 cat remained
hyperthyroid, and 2 cats had uncertain thyroid status at T1 because
of the missing sTSH concentrations. At T2, there were 18 euthyroid
cats, 7 subclinically hypothyroid cats, and 1 iatrogenic hyperthyroid
cat because of levothyroxine overdose. All 49 cats were nonazotemic
at both T0 and T1. Only 2 euthyroid cats developed post-treatment
azotemia (IRIS stages 2 and 4) at T2. The GFR measurement was per-
formed in 11 hyperthyroid cats at 3 time points, and 1 cat at 2 time
points (T0 and T1). All 12 cats had normal GFR at T0. At T1, borderline
low GFR was present in 2 cats and low GFR was presented in 1 cat.
At T2, 5 of 11 cats had borderline low GFR. None of the cats with
GFR measurements were azotemic either at T1 or T2.
3.2 | Comparison of L-FABP and NGAL between
CKD cats, hyperthyroid cats, and healthy cats
Serum L-FABP concentrations were measured in all CKD (9) and
healthy cats (45) and in 40 of 49 hyperthyroid cats. Serum NGAL
(sNGAL) concentrations were evaluated in 38 of 49 hyperthyroid cats.
The concentrations of uL-FABP and uNGAL were measured in 44 of
45 healthy cats. All missing measurements were related to inadequate
remaining sample volumes.
There were significant differences in sL-FABP and uL-FABP/Cr
measurements between groups (Figure 1). Cats with CKD had signifi-
cantly higher sL-FABP and uL-FABP/Cr values than healthy cats. The uri-
nary L-FABP concentration was <LOD in 3 (33%) of 9 CKD cats, 9 (18%)
of 49 hyperthyroid cats, and in 41 (93%) of 44 healthy cats. The 6 CKD
cats with detectable uL-FABP had IRIS stage 2 to 4 CKD, while the
remaining CKD cats with uL-FABP <LOD all had stage 3.
In hyperthyroid cats, the uL-FABP/Cr was significantly higher than
in healthy cats There were no significant differences in sL-FABP
TABLE 1 Descriptive statistics of
selected clinical and laboratory variables




Sex (male/total) 6/9 24/49 20/45
Age (years) 6a [5, 9] 12b [10, 14] 6a [3, 8]
Body weight (kg) 3.7 [3.2,5.0] 3.7 [3.4-4.3] 4.0 [3.4-4.9]
SBP (mmHg) 145 [140, 151] 155 [140, 180] 146 [130, 158]
sCr (mg/dL) 3.43a [2.76, 4.07] 0.69b [0.57, 0.97] 1.23c [1.06, 1.37]
USG 1.019a [1.017, 1.020] 1.050b [1.036, 1.050] 1.049b [1.042, 1.054]
UPC 0.2a,b [.1, .8] 0.5a, [0.4, 0.8] 0.1b [0.1, 0.2]
Note: Data are presented as medians [25th and 75th percentiles], except for sex (proportions). Medians in
a row with different superscripts (a,b,c) differ significantly.
Abbreviations: CKD, chronic kidney disease; SBP, systolic blood pressure; sCr, serum creatinine; UPC,
urinary protein-to-creatinine ratio; USG, urine specific gravity.
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concentrations between hyperthyroid and CKD cats. No significant dif-
ferences in sNGAL and uNGAL/Cr were observed between groups
(Figure 2).
3.3 | Receiver operating characteristic analysis of
L-FABP and NGAL for the detection of azotemic CKD
Receiver operating characteristic analysis illustrated the ability of L-
FABP and NGAL to distinguish azotemic CKD cats from healthy cats.
For sL-FABP, a cutoff of ≥13.50 ng/mL had 55.6% [95% CI,
21.2-86.3] sensitivity and 88.9% [95% CI, 76.0-96.3] specificity. Five
(11%) of 45 healthy cats showed sL-FABP concentrations greater than
the cutoff. For uL-FABP/Cr, a cutoff of ≥0.97 μg/g had a 100% [95%
CI, 66.4-100.0] sensitivity and 93.2% [95% CI, 81.3-98.6] specificity
(Figure 3). Three of 44 healthy cats had uL-FABP/Crs greater than the
cutoff.
The cutoff for sNGAL was ≥48.38 ng/mL, which had a sensitivity of
33.3% [95% CI, 7.48-70.1] and a specificity of 84.4% [95% CI, 70.5-93.5].
The sensitivity and specificity were 55.6% [95% CI, 21.2-86.3] and 93.2%
[95% CI, 81.3-98.6] for uNGAL/Cr with a cutoff of ≥7.39 μg/g. Three of
44 healthy cats had uNGAL/Crs greater than the cutoff.
3.4 | Comparison of L-FABP and NGAL in
hyperthyroid cats before and after 131I treatment
Serum L-FABP concentration did not significantly differ between T0
and T2 and between T1 and T2 (Figure 4A). Urinary L-FABP/Cr signif-
icantly decreased at T2 compared to T0 while it did not significantly
differ between T0 and T1 and between T1 and T2 (Figure 4B). At T0,
uL-FABP concentration was significantly different from T1 (P < .001)
and T2 (P = .003). The concentration of uL-FABP at the different time
points is shown in Figure 5A. This concentration was less than LOD in
TABLE 2 Selected clinical and
laboratory variables of hyperthyroid cats
before (T0), 1 month (T1), and 11 to
29 months after (T2) 131I treatment
T0 T1 T2
Variables
Body weight (kg) 3.7a [3.4, 4.3] 4.1b [3.5, 4.6] 4.1c [3.6, 4.9]
SBP (mmHg) 155 [140, 180] 165 [140, 180] 170 [150, 182]
sTT4 (μg/dL) 8.1a [6.5, 12] 0.9b [0.7, 1.3] 1.7c [1.4, 2.0]
sTSH (ng/mL) <0.03a [<0.03, <0.03] 0.09b [<0.03, 0.15] 0.17c [0.07, 0.35]
sCr (mg/dL) 0.69a [0.57, 0.97] 1.29b [0.98, 1.50] 1.54c [1.35, 1.77]
USG >1.050a [1.035, >1.050] 1.042b [1.028, >1.050] 1.036b [1.021, 1.050]
UPC 0.5a [0.4, 0.8] 0.2b [0.1, 0.3] 0.2b [0.1, 0.3]
GFR (mL/kg/minute) 3.2a [2.8, 4.2] 2.1b [1.9,2.3] 2.0b [1.6, 2.5]
Note: Data are presented as median [25th and 75th percentiles]. Medians in a row with different
superscripts (a,b,c) differ significantly.
Abbreviations: GFR, glomerular filtration rate; SBP, systolic blood pressure; sCr, serum creatinine; sTSH,
serum thyroid stimulating hormone; sTT4, serum total thyroxine; UPC, urinary protein-to-creatinine ratio;
USG, urine specific gravity.
F IGURE 1 Box and whisker plots showing L-FABP in CKD cats,
hyperthyroid cats, and healthy cats. A, sL-FABP concentrations in
CKD cats (n = 9), hyperthyroid cats (n = 40), and healthy cats (n = 45)
and their significant differences. B, uL-FABP/Cr in CKD cats (n = 9),
hyperthyroid cats (n = 49), and healthy cats (n = 44) and their
significant differences. Whiskers represent the min and max values.
CKD, chronic kidney disease; L-FABP, liver-type fatty acid-binding
protein; sL-FABP, serum L-FABP; uL-FABP/Cr, urinary L-FABP-to-
creatinine ratio
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32 (65%) of 49 cats at T0, in 47 (96%) of 49 cats at T1, and 23 (89%)
of 26 cats at T2.
Serum NGAL concentration significantly decreased at T2 com-
pared to T0 and T1. There was no significant different in sNGAL con-
centration between T0 and T1 (Figure 6A). Urinary NGAL/Cr did not
significantly change between time points (Figure 6B). The concentra-
tion of uNGAL was not significantly different between time points.
The concentration of uL-FABP at the different time points is pres-
ented in Figure 5B.
Comparison of both renal biomarkers (L-FABP and NGAL) from
T0 to T2 between the subgroup of cats with different GFR status at
T2 is described in Table S2.
3.5 | Correlations between L-FABP and NGAL and
routine renal variables
Spearman's correlations between both renal biomarkers (L-FABP and
NGAL) and 2 routine renal variables, namely sCr and UPC, were
assessed in CKD cats and in healthy cats. The data are presented in
Table 3.
Significant correlations between sL-FABP and sCr and between
sL-FABP and UPC were weak and moderate, respectively. Urinary L-
FABP/Cr was weakly and significantly correlated with both sCr and
UPC. There were no significant correlations between sNGAL and both
sCr and UPC. The correlation between uNGAL/Cr and sCr was not
significant, whereas the correlation between uNGAL/Cr and UPC was
weak and significant.
In hyperthyroid cats before and after 131I treatment, Spearman's
correlations between both renal biomarkers (L-FABP and NGAL) and
selected variables including sCr, UPC, sTT4, and GFR at different time
points were calculated and reported in Table 4.
Urinary LFABP/Cr significantly correlated with UPC at all time
points with a moderate correlation at both T0 and T2 and with a weak
correlation at T1. A moderate and significant correlation was observed
between GFR and uL-FABP/Cr at T0. The correlations between
uNGAL/Cr and UPC were significant at T1 and T2 with weak and
strong correlations, respectively. At all time points, sL-FABP and
sNGAL did not correlate with all selected variables, uL-FABP/Cr did
not correlate with sCr and sTT4, and uNGAL/Cr did not correlate with
sCr, GFR, and sTT4.
3.6 | Correlations between serum and urinary
concentrations for L-FABP and NGAL
Spearman's correlation analyzes demonstrated that log sL-FABP con-
centrations were significantly correlated with the log uL-FABP/Cr
F IGURE 2 Box and whisker plots showing NGAL in CKD cats,
hyperthyroid cats, and healthy cats. A, sNGAL concentrations in CKD
cats (n = 9), hyperthyroid cats (n = 38), and healthy cats (n = 45) and
their significant differences. B, uNGAL/Cr in CKD cats (n = 9),
hyperthyroid cats (n = 49), and healthy cats (n = 44). Whiskers
represent the min and max values. CKD, chronic kidney disease;
NGAL, neutrophil gelatinase-associated lipocalin; sNGAL, serum
NGAL; uNGAL/Cr, urinary NGAL-to-creatinine ratio
F IGURE 3 Receiver operating characteristic curve displaying the
sensitivity and specificity of urinary L-FABP-to-creatinine ratio as a
diagnostic test for azotemic chronic kidney disease (CKD) in cats with
azotemic CKD (n = 9) and healthy cats (n = 45)
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values in CKD cats and healthy cats (ρ = .31; P = .03; Figure 7A). There
was no significant correlation between log sNGAL and log uNGAL/Cr
in CKD cats and healthy cats (ρ = .18; P = .21; Figure 7B).
In hyperthyroid cats before and after 131I treatment, Spearman's
correlations between sL-FABP and uL-FABP/Cr were not significant
in hyperthyroid cats at all time points. There were no significant corre-
lations between sNGAL and uNGAL/Cr in cats at all time points.
4 | DISCUSSION
In the present study, we investigated the diagnostic utility of L-FABP
for detecting azotemic CKD in cats. Furthermore, this is the first study
to evaluate both serum and urinary L-FABP as well as NGAL in hyper-
thyroid cats. The main findings of this study are: (a) CKD cats have
significantly higher sL-FABP and uL-FABP values than healthy cats;
(b) most healthy cats have a uL-FABP concentration below the LOD;
(c) sL-FABP significantly correlated with uL-FABP/Cr in CKD cats and
in healthy cats; (d) both sNGAL and uNGAL values are not different
between CKD, hyperthyroid, and healthy cats; (e) ROC analysis indi-
cated that uL-FABP/Cr was superior to sL-FABP, sNGAL, and
uNGAL/Cr for differentiating azotemic CKD from healthy cats; (f)
hyperthyroid cats have higher uL-FABP values compared to healthy
cats and these values normalize after restoring euthyroidism.
CKD cats had significantly higher s L-FABP concentration than
healthy cats. This observation is compatible with findings in human
studies. Indeed, significantly higher sL-FABP concentrations are
detected in patients with end-stage renal disease compared to healthy
volunteers.54 In addition, the significant correlation between sL-FABP
and sCr we observed is in line with findings described in human CKD
patients.55 Using a cutoff of 13.5 ng/mL, an increased sL-FABP con-
centration was present in half of the CKD cats with a specificity
approximating 90%. An unexpected finding was that sL-FABP in CKD
cats varied widely regardless of IRIS stage. Although careful interpre-
tation is warranted considering the low number of CKD cats included
in the current study, the explanation is not obvious. Little is known
about the mechanism causing an increased sL-FABP concentration in
patients with CKD. In healthy individuals, circulatory L-FABP mainly
originates from the liver and is increased in patients with liver
F IGURE 4 Box and whisker plots showing L-FABP in
hyperthyroid cats before (T0), 1 month (T1), and 11 to 29 months
after (T2) 131I treatment. A, sL-FABP concentrations in cats at T0
(n = 40), T1 (n = 42), and T2 (n = 22). B, uL-FABP/Cr in cats at T0
(n = 49), T1 (n = 49), and T2 (n = 26). Whiskers represent the min and
max values. L-FABP, liver-type fatty acid-binding protein; sL-FABP,
serum L-FABP; uL-FABP/Cr, urinary L-FABP-to-creatinine ratio
F IGURE 5 The concentrations of (A) uL-FABP and (B) uNGAL in
hyperthyroid cats before (T0, n = 49), 1 month (T1, n = 49), and 11 to
29 months after (T2, n = 26) 131I treatment. L-FABP, liver-type fatty
acid-binding protein; NGAL, neutrophil gelatinase-associated lipocalin;
uL-FABP/Cr, urinary L-FABP-to-creatinine ratio; uNGAL/Cr, urinary
NGAL-to-creatinine ratio
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disease.55 Serum L-FABP is filtered through the kidney, so its accumu-
lation may be caused by a decreased GFR in patients with CKD. If this
hypothesis is true, sL-FABP concentrations would be expected to be
associated with IRIS stage in CKD cats. Another theory is that upon
tubulointerstitial injury, uL-FABP may be reabsorbed by the still intact
proximal tubules, thereby increasing sL-FABP.56 Cats with CKD may
have different degrees of tubulointerstitial damage, so renal biopsy
would be beneficial to further evaluate L-FABP expression in relation
to the renal pathology present in those cats.
Five of the 45 healthy cats showed sL-FABP concentrations
greater than the cutoff. Concurrent (liver) disease seems unlikely, as
these cats were thoroughly screened at inclusion. None of them
became azotemic during 7 months of follow-up, suggesting that early
CKD is unlikely in these 5 cats. Nevertheless, whether or not the
increased sL-FABP in these non-azotemic cats did or did not originate
from renal injury is impossible to determine without renal histopatho-
logical assessment.
Urinary L-FABP/Cr was significantly increased in CKD cats com-
pared to healthy cats. This outcome is comparable to human studies
showing significant increases in uL-FABP/Cr in patients with
CKD.21,24,55,57 Six (67%) of 9 CKD cats had measurable uL-FABP con-
centrations, corroborating a recent study reporting high uL-FABP/Cr
values in 18/34 (53%) cats with azotemic CKD.26 As tubulointerstitial
inflammation is a predominant feature of CKD in cats, upregulated
uL-FABP was expected.58 Moreover, uL-FABP/Cr levels correlate
with the degree of tubulointerstitial damage and predicted CKD pro-
gression in humans.21,26 Tubulointerstitial inflammation does not dif-
fer according to stage in cats with IRIS stage 2-4 CKD.21,57 Hence,
variations in uL-FABP/Cr may be because of different severities of
tubular damage and may indicate a variable CKD progression rate in
cats. The significant correlation between uL-FABP/Cr and sCr in this
observation along with data in humans and CKD cats supports the
hypothesis that uL-FABP concentrations increase as kidney function
declines.21,26 Still, given the limited number of CKD cats in the pre-
sent study, it is difficult to determine a relationship between the
severity of azotemia and uL-FABP/Cr values. A longitudinal study of
uL-FABP in CKD cats including renal biopsy would allow the evalua-
tion of its ability to monitor CKD progression.
Another possible cause for increased uL-FABP in CKD cats could
be the effect from proteinuria since a significant correlation was
observed between uL-FABP/Cr and UPC in the group of CKD cats
and healthy cats. These results corroborate findings in humans with
CKD.20 The possible reason could be that massive proteinuria, which
is uncommon in the cats of the present study and in the overall popu-
lation of CKD cats,59 causes tubulointerstitial damage by overloading
proximal tubules with free fatty acids. This damages tubular cells and
induces L-FABP excretion into urine.20,60 An alternative explanation
could be a lack of reabsorption mechanism of filtered L-FABP second-
ary to protein overload and the saturation of protein reuptake mecha-
nism in proximal tubules, which is described for increased urinary N-
acetyl-β-d-glucosaminidase excretion in CKD cats.61
F IGURE 6 Box and whisker plots showing NGAL in hyperthyroid
cats before (T0), 1 month (T1), and 11 to 29 months after (T2) 131I
treatment. A, NGAL concentrations in cats at T0 (n = 38), T1 (n = 41),
and T2 (n = 22). B, uNGAL/Cr in cats at T0 (n = 49), T1 (n = 49), and
T2 (n = 26). Whiskers represent the min and max values. NGAL,
neutrophil gelatinase-associated lipocalin; sNGAL, serum NGAL;
uNGAL/Cr, urinary NGAL-to-creatinine ratio
TABLE 3 Spearman's correlations (ρ) between L-FABP and NGAL
values and routine renal variables in cats with CKD and healthy
cats (n = 54)
Variables
sCr UPC
ρ P ρ P
sL-FABP .30 .03 .47 < .001
uL-FABP/Cr .28 .06 .35 .01
sNGAL −.03 .86 .15 .27
uNGAL/Cr .08 .57 .29 .03
Abbreviations: CKD, chronic kidney disease; L-FABP, liver-type fatty acid-
binding protein; NGAL, neutrophil gelatinase-associated lipocalin; sCr,
serum creatinine; sL-FABP, serum L-FABP; sNGAL, serum NGAL; uL-
FABP/Cr, urinary L-FABP-to-creatinine ratio; uNGAL/Cr, urinary NGAL-
to-creatinine ratio; UPC, urinary protein-to-creatinine ratio.
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Corroborating a recent study, we found that most healthy cats
have uL-FABP concentrations lesser than LOD except for 3 cats.25,26
As noted for sL-FABP, early CKD cannot be completely excluded in
these cats. In humans, uL-FABP is a highly sensitive marker of tubular
injury, which makes uL-FABP a promising biomarker of early kidney
disease.21,22,62 Further studies on a large population of initially non-
azotemic healthy cats should establish the ability of uL-FABP to
detect early CKD in healthy cats.
Similar to a recent study in cats with various kidney conditions,
sL-FABP concentration and uL-FABP/Cr were significantly correlated
in the group of CKD cats and healthy cats, suggesting the variables
are co-dependent in cats.26 This contrasts to the finding in patients
with CKD where sL-FABP and uL-FABP concentrations are not corre-
lated.55 Since sL-FABP is produced mainly by the liver, these findings
suggest that liver disease that may increase sL-FABP concentration
should be ruled out when interpreting uL-FABP/Cr as a renal bio-
marker in cats.20 Further studies on the influence of nonrenal factors
on L-FABP concentrations are warranted.
The sNGAL concentration did not statistically differ between
CKD cats and healthy cats. Our data corroborate a recent study show-
ing no difference in plasma NGAL (pNGAL) concentrations between
CKD cats and healthy cats.43 The median sNGAL concentrations in
our study were much lower than the median pNGAL concentrations
reported in the aforementioned study (31.33 ng/mL vs. 211.07 ng/mL
in healthy cats)43, probably because of the different ELISAs used in
the 2 studies. More specifically, for pNGAL, an in-house ELISA was
used based on an anticanine NGAL capture antibody, whereas we
used a commercial ELISA with an antihuman NGAL antibody.43
Although both of these capture antibodies are claimed to cross-react
with feline NGAL, their affinities to feline NGAL are probably differ-
ent. Indeed, homologies between human and feline NGAL and
between canine and feline NGAL are 64% and 60%, respectively,
using BLAST. Another explanation for the discordant results is that
the high pNGAL concentration might be attributed to non-specific
binding, since the accuracy of that ELISA was not provided. In addi-
tion, we observed different values between sNGAL and pNGAL in a
preliminary study (Table S3).
Urinary NGAL/Cr did not significantly differ between CKD cats
and healthy cats. In contrast, previous studies have shown that
uNGAL/Cr is higher in CKD cats compared to healthy cats and even
associated with IRIS stage.43,63 The reason for these discrepant results
is unclear. Corroborating a previous study, the present study demon-
strated a poor correlation between sNGAL and uNGAL suggesting
that, in cats, sNGAL does not influence uNGAL.43
ROC analysis demonstrated that L-FABP outperforms NGAL for
the detection of azotemic CKD. More specifically, the ability of uL-
FABP/Cr to detect azotemic CKD in CKD and healthy cats outper-
forms the ability of sL-FABP because of the greater sensitivity and
specificity.
To our knowledge, the effect of naturally occurring hyperthyroid-
ism on sL-FABP and uL-FABP levels has not been reported in any spe-
cies. This study demonstrated that uL-FABP/Cr was increased in
hyperthyroid cats and normalized after treatment. Although there was
no significant difference in uL-FABP/Cr between hyperthyroid cats at
TABLE 4 Spearman's correlations (ρ)
between L-FABP and NGAL values and
selected laboratory variables in
hyperthyroid cats at before (T0), 1 month
(T1), and 11 to 29 months after 131I
treatment (T2)
Variables
sL-FABP uL-FABP/Cr sNGAL uNGAL/Cr
ρ P ρ P ρ P ρ P
sCr
T0 .18 .26 −.19 .17 −.14 .41 .22 .13
T1 .11 .49 .17 .24 −.10 .55 .06 .67
T2 .11 .62 .19 .35 −.35 .11 −.02 .92
UPC
T0 −.06 .68 .66 <.001 .63 .16 .02 .87
T1 .20 .20 .31 .03 .02 .90 .30 .04
T2 .05 .83 .67 <.001 .28 .21 .78 <.001
GFR
T0 −.63 .13 .58 .05 .42 .30 −.03 .27
T1 −.09 .80 .16 .62 .49 .18 −.36 .26
T2 .13 .68 .12 .72 −.04 .92 −.07 .83
sTT4
T0 −.28 .75 .11 .47 .17 .75 −.16 .94
T1 .16 .32 −.10 .48 −.06 .87 .07 .63
T2 −.17 .44 −.09 .65 −.36 .10 .002 .99
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate; L-FABP, liver-type fatty acid-
binding protein; NGAL, neutrophil gelatinase-associated lipocalin; sCr, serum creatinine; sL-FABP, serum
L-FABP; sNGAL, serum NGAL; sTT4, serum total thyroxine; uL-FABP/Cr, urinary L-FABP-to-creatinine
ratio; uNGAL/Cr, urinary NGAL-to-creatinine ratio; UPC, urinary protein-to-creatinine ratio.
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T0 and T1, a significant difference was observed in uL-FABP concen-
tration. Furthermore, the percentage of cats with uL-FABP
concentration < LOD in hyperthyroid cats after treatment and in
healthy cats were similar, suggesting that uL-FABP concentration in
hyperthyroid cats generally normalizes after treatment. These findings
are consistent with a number of studies in hyperthyroid cats evaluat-
ing other tubular biomarkers, which are all increased before treatment
and normalize following treatment.64-66
Comparable to previous studies, our study showed uL-FABP's
ability to detect CKD in cats. Therefore, it is possible that the
increased uL-FABP concentration reflects masked CKD in cats with
hyperthyroidism.25,26 We found that uL-FABP concentration was
greater than LOD in 35% of hyperthyroid cats before treatment,
which was similar to the percentage of cats that has been reported to
develop post-treatment azotemia (15%-40%).21,55,67 Unfortunately,
the very limited number of post-treatment azotemic cats in this study
impedes the evaluation of uL-FABP to predict post-treatment azote-
mia. Another explanation could be that thyrotoxicosis might directly
increase sL-FABP and filtered L-FABP concentrations, leading to an
increase in uL-FABP concentration. One preclinical study in experi-
mentally induced hyperthyroid rats shows an increased level of L-
FABP in hepatocyte cytosol.41 However, we observed poor correla-
tions between sTT4 and both sL-FABP and uL-FABP/Cr and between
sL-FABP and uL-FABP/Cr in hyperthyroid cats before and after treat-
ment. Also, sL-FABP concentration in hyperthyroid cats did not differ
from healthy cats and remained unchanged after treatment. There-
fore, the direct effect of hyperthyroidism to increased uL-FABP in
cats remains unclear. Alternatively, increased uL-FABP excretion may
reflect a lack of reuptake mechanism of filtered L-FABP in urine
because of proteinuria.61 Supporting this hypothesis, our study found
a moderate and significant association between UPC and uL-FABP in
hyperthyroid cats before and after treatment.
Neither sNGAL concentrations nor uNGAL/Cr values differed
significantly between hyperthyroid cats and healthy cats in the
cross-sectional study. These results show that hyperthyroidism
may not affect sNGAL and uNGAL concentration in cats. However,
in the longitudinal study, sNGAL concentration in hyperthyroid cats
before treatment was significantly decreased upon euthyroidism.
One report in humans also observes no significant difference in
pNGAL levels between hyperthyroid and euthyroid patients.68
With a very limited data regarding the sNGAL expression in cats
and other species with hyperthyroidism, the reason of these con-
flicting results remains unclear. Currently, there are no data regard-
ing the relationship between thyroid dysfunction and uNGAL
expression.
A limitation of our study is the limited number of CKD. Also, only
2 hyperthyroid cats developed post-treatment azotemia we cannot
conclude on the prediction of post-treatment azotemia. Post-
treatment azotemia in hyperthyroid cats treated with fixed dose pro-
tocols of 131I is present in 15% to 46% of all cats.48,69 The lower num-
ber of post-treatment azotemic cats (8%) in this study is probably
because of the adjusted dose protocol of 131I used at our university
for many years, which is based on the severity of hyperthyroidism and
size of the thyroid glands in each cat. In contrast to the fixed dose
method, the adapted dose protocol may give more suitable dose of
131I for hyperthyroid cats and may result in lower number of cats with
iatrogenic hypothyroidism and post-treatment azotemia.70 Thirdly,
the timing of the assessment at T2 (11-29 months) was variable
between cats. This may have affected the variability of the measured
variables at this time point. The values of L-FABP and NGAL may
increase at the time of tubular injury and gradually decrease over time
so there is a possibility that we missed the time frame when these
biomarkers reached their peak levels.25,37 Another potential limitation
was that a long-term frozen storage might have affected the mea-
sured concentrations of both L-FABP and NGAL. However, in
humans, uL-FABP concentrations do not significantly change after
storage at −70C for 18 months.71 Again, in human samples, urinary
NGAL is found to be stable at −80C when stored for up to 5 years.72
Lastly, the antibodies in the feline L-FABP and NGAL ELISA kits used
in this study were antihuman, consequently the obtained concentra-
tions are relative to humans instead of absolute concentrations in
cats. Hence, comparisons of L-FABP and NGAL concentrations and
ratio to Cr within species are acceptable, but not between humans
and cats.
F IGURE 7 Spearman's correlation between serum and urinary
biomarkers in cats. A, The correlation between log sL-FABP and log
uL-FABP/Cr in the group of cats with CKD and healthy cats (n = 53).
B, The correlation between Log sNGAL and Log uNGAL/Cr in the
group of cats with CKD and healthy cats (n = 53)
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5 | CONCLUSION
Only urinary L-FABP/Cr distinguished CKD cats from healthy cats,
suggesting that uL-FABP might be a promising biomarker of early renal
impairment in cats. The increased uL-FABP concentration in hyperthy-
roid cats probably reflects renal insult in hyperthyroidism and resolved
when euthyroidism was obtained. Nevertheless, the predictive value of
uL-FABP for prediction of post-treatment azotemia in hyperthyroid
cats remains uncertain. In contrast to uL-FABP/Cr, NGAL in both serum
and urine is not a useful biomarker of renal dysfunction in cats.
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